Tg Therapeutics Stock News

The FDA asked for an adcomm over OS concerns and brought down TGTX stock. OS was not a part of the agreed upon study protocol, and data was not mature, and study was not powered for OS.

TG Therapeutics, Inc. (NASDAQ:TGTX) Equities research analysts at B. Riley cut their FY2022 EPS estimates for TG Therapeutics in a research report issued to clients and investors on Tuesday, November 30th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post earnings of ($2.91) per share for the year, down from []

NEW YORK, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against TG Therapeutics, Inc. (TG Therapeutics or the Company) (NASDAQ: TGTX) on behalf of TG Therapeutics stockholders. Our investigation concerns whether TG Therapeutics has violated the federal securities laws and/or engaged in other unlawful business practices.

TG Therapeutics (NASDAQ:TGTX) had its target price cut by Evercore ISI from $55.00 to $36.00 in a research note published on Wednesday morning, PriceTargets.com reports. They currently have an outperform rating on the biopharmaceutical companys stock. A number of other analysts also recently issued reports on the stock. HC Wainwright cut their price objective on []

TG Therapeutics (NASDAQ:TGTX) had its price target lowered by The Goldman Sachs Group from $26.00 to $13.00 in a research report sent to investors on Wednesday, Analyst Price Targets reports. The Goldman Sachs Group currently has a sell rating on the biopharmaceutical companys stock. Several other equities analysts have also recently weighed in on the []

TG Therapeutics (NASDAQ:TGTX) had its price objective dropped by equities research analysts at The Goldman Sachs Group from $26.00 to $13.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has a sell rating on the biopharmaceutical companys stock. The Goldman Sachs Groups price target points to a potential downside of []

Wall Street brokerages expect that TG Therapeutics, Inc. (NASDAQ:TGTX) will report sales of $11.56 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for TG Therapeutics earnings, with the lowest sales estimate coming in at $3.50 million and the highest estimate coming in at $32.84 million. TG Therapeutics []

NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of TG Therapeutics, Inc. (TG Therapeutics or the Company) (NASDAQ: TGTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Investors are rattled by the FDA's request for an out-of-the-ordinary meeting dedicated to scrutinizing the company's latest drug approval request.

Investors are rattled by the FDA''s request for an out-of-the-ordinary meeting dedicated to scrutinizing the company''s latest drug approval request.

TG Therapeutics is unlikely to make its goal date to review its application for "U2"

TG Therapeutics Inc (NASDAQ: TGTX) shares are falling after FDA notified the Company that it plans to host an Oncologic Drugs Advisory Committee (ODAC) meeting for marketing application regarding ubl